表紙
市場調查報告書
商品編碼
1019183

全球肝炎治療藥市場規模調查:各疾病類型,各地區預測(2021∼2027年)

Global Hepatitis Therapeutics Market Size study, by Disease Type (Hepatitis A, B, C and Others) and Regional Forecasts 2021-2027

出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球肝炎治療藥的市場規模在2020年估算為約215億美金。

該市場在2021年∼2027年的預測期間內,預計將以2.3%以上健全的成長率增長。

肝炎是一種引起肝臟炎症的疾病,會導致多種健康問題,並且可能是致命的。肝炎病毒通常有五種主要毒株,稱為A型、B型、C型、D型和E型。世界範圍內病毒性肝炎的發病率不斷增加,自身免疫性疾病的數量不斷增加,全球醫療保健成本不斷增加,推動了肝炎藥物市場的發展。根除這種疾病至關重要,因為肝炎死亡人數高於艾滋病毒和結核病死亡人數。

根據世界衛生組織 2019 年的數據,全球約有 3.25 億人患有乙型和/或丙型肝炎。在全球範圍內,估計有 7100 萬人感染了慢性丙型肝炎病毒。世衛組織的全球肝炎戰略旨在在 2016 年至 2030 年期間將新發肝炎感染和死亡人數大幅減少 90% 和 65%。該戰略已獲得世衛組織所有成員國的批准。到 2030 年,疫苗接種、診斷測試和藥物治療將防止中低收入國家 450 萬人過早死亡。抗病毒藥物可以治療近 95% 的丙型肝炎感染患者,從而降低因肝硬化和肝癌而死亡的風險。低收入國家缺乏治療設施和醫療保健機會不足預計將成為肝炎藥物市場增長的驅動因素。然而,預計政府和國際組織在資金、監管和戰略方面的更多努力將為未來十年的肝炎藥物市場提供機會。

本報告提供全球肝炎治療藥市場相關調查,提供市場概要,以及各疾病類型,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 全球肝炎治療藥市場定義和範圍

第3章 全球肝炎治療藥市場動態

  • 肝炎治療藥市場影響分析(2019∼2027年)

第4章 全球肝炎治療藥市場產業分析

  • 波特的五力分析
  • PEST分析
  • 投資採用模式
  • 分析師的推薦事項與結論

第5章 全球肝炎治療藥市場,各疾病類型

  • 市場概述
  • 全球肝炎治療藥市場,各疾病類型:效能-潛在的分析
  • 全球肝炎治療藥市場預算與預測,各疾病類型:2018∼2027年(10億美元)
  • 肝炎治療藥市場,子區隔分析
    • A型肝炎
    • B型肝炎
    • C型肝炎
    • 其他

第6章 全球肝炎治療藥市場,地區分析

  • 地區市場概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲概述
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區的概述
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 其他
  • 南美概述
    • 巴西
    • 墨西哥
  • 其他地區

第7章 競爭資訊

  • 頂級市場策略
  • 企業簡介
  • Gilead Lifesciences
    • Bristol-Myers Squibb Co
    • Biocon
    • AbbVie
    • Merck & Co., Inc.,
    • Johnson & Johnson
    • Roche
    • Novartis
    • Sanofi
    • Cipla

第8章 調查流程

目錄

Global Hepatitis Therapeutics Market is valued approximately USD 21.5 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 2.3% over the forecast period 2021-2027. Hepatitis is a disease which causes inflammation of the liver which causes a range of health problems and can lead to death. There are generally five main strains of the hepatitis virus, which are referred as types A, B, C, D and E. The growing incidences of viral hepatitis across globe, rise in the number of autoimmune diseases, coupled with increased healthcare expenditures worldwide, are driving the Hepatitis Therapeutics market. The number of death caused by hepatitis is more than the deaths caused by HIV and TB, and hence the eradication of diseases is of prime importance. According to World Health Organization in 2019, approximately 325 million people suffer from hepatitis B and/or C worldwide. Globally, an estimated 71 million people have chronic hepatitis C virus infection. WHO's global hepatitis strategy aims to reduce new hepatitis infections by significant 90% and deaths by 65% between 2016 and 2030. This strategy is endorsed by all WHO members. It also states that 4.5 million premature deaths can be prevented in low and middle-income countries by 2030 through vaccination, diagnostic tests and medicines. Antiviral medicines can treat nearly 95% of patients with hepatitis C infection, thereby reducing the risk of death from cirrhosis and liver cancer. The lack of treatment facilities available in low-income nations and poor healthcare accessibility may act as a restraint for hepatitis therapeutics market growth. However, increasing efforts from government as well as international organizations in the form of funds, regulations and strategies act as an opportunity for Hepatitis Therapeutics Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Hepatitis Therapeutics Market. Due to higher investment in therapeutic treatment as well as higher per capita income, North America has emerged as a significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit the highest growth rate for the forecast period 2021-2027 owing to the growing hepatitis prevalence in underdeveloped areas of the region. Rising disposable income and growing GDPs of many countries will also boost growth in this region.

Major market player included in this report are:

Gilead Lifesciences

Bristol-Myers Squibb Co

Biocon

AbbVie

Merck & Co., Inc.,

Johnson & Johnson

Roche

Novartis

Sanofi

Cipla

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease Type:

Hepatitis A

Hepatitis B

Hepatitis C

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027

Target Audience of the Global Hepatitis Therapeutics Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
    • 1.2.1. Hepatitis Therapeutics Market, by Disease Type, 2019-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hepatitis Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hepatitis Therapeutics Market Dynamics

  • 3.1. Hepatitis Therapeutics Market Impact Analysis (2019-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidences of hepatitis across world
      • 3.1.1.2. Rising expenditure in healthcare sector
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of medical facilities in low-income countries
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing governmental and global efforts to curb hepatitis

Chapter 4. Global Hepatitis Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Hepatitis Therapeutics Market, by Disease Type

  • 5.1. Market Snapshot
  • 5.2. Global Hepatitis Therapeutics Market by Disease Type, Performance - Potential Analysis
  • 5.3. Global Hepatitis Therapeutics Market Estimates & Forecasts by Disease Type 2018-2027 (USD Billion)
  • 5.4. Hepatitis Therapeutics Market, Sub Segment Analysis
    • 5.4.1. Hepatitis A
    • 5.4.2. Hepatitis B
    • 5.4.3. Hepatitis C
    • 5.4.4. Others

Chapter 6. Global Hepatitis Therapeutics Market, Regional Analysis

  • 6.1. Hepatitis Therapeutics Market, Regional Market Snapshot
  • 6.2. North America Hepatitis Therapeutics Market
    • 6.2.1. U.S. Hepatitis Therapeutics Market
      • 6.2.1.1. Disease Type breakdown estimates & forecasts, 2018-2027
    • 6.2.2. Canada Hepatitis Therapeutics Market
  • 6.3. Europe Hepatitis Therapeutics Market Snapshot
    • 6.3.1. U.K. Hepatitis Therapeutics Market
    • 6.3.2. Germany Hepatitis Therapeutics Market
    • 6.3.3. France Hepatitis Therapeutics Market
    • 6.3.4. Spain Hepatitis Therapeutics Market
    • 6.3.5. Italy Hepatitis Therapeutics Market
    • 6.3.6. Rest of Europe Hepatitis Therapeutics Market
  • 6.4. Asia-Pacific Hepatitis Therapeutics Market Snapshot
    • 6.4.1. China Hepatitis Therapeutics Market
    • 6.4.2. India Hepatitis Therapeutics Market
    • 6.4.3. Japan Hepatitis Therapeutics Market
    • 6.4.4. Australia Hepatitis Therapeutics Market
    • 6.4.5. South Korea Hepatitis Therapeutics Market
    • 6.4.6. Rest of Asia Pacific Hepatitis Therapeutics Market
  • 6.5. Latin America Hepatitis Therapeutics Market Snapshot
    • 6.5.1. Brazil Hepatitis Therapeutics Market
    • 6.5.2. Mexico Hepatitis Therapeutics Market
  • 6.6. Rest of The World Hepatitis Therapeutics Market

Chapter 7. Competitive Intelligence

  • 7.1. Top Market Strategies
  • 7.2. Company Profiles
  • 7.3. Gilead Lifesciences
      • 7.3.1.1. Key Information
      • 7.3.1.2. Overview
      • 7.3.1.3. Financial (Subject to Data Availability)
      • 7.3.1.4. Product Summary
      • 7.3.1.5. Recent Developments
    • 7.3.2. Bristol-Myers Squibb Co
    • 7.3.3. Biocon
    • 7.3.4. AbbVie
    • 7.3.5. Merck & Co., Inc.,
    • 7.3.6. Johnson & Johnson
    • 7.3.7. Roche
    • 7.3.8. Novartis
    • 7.3.9. Sanofi
    • 7.3.10. Cipla

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Hepatitis Therapeutics Market, report scope
  • TABLE 2. Global Hepatitis Therapeutics Market estimates & forecasts by region 2018-2027 (USD Billion)
  • TABLE 3. Global Hepatitis Therapeutics Market estimates & forecasts by Disease Type 2018-2027 (USD Billion)
  • TABLE 4. Global Hepatitis Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 5. Global Hepatitis Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 6. Global Hepatitis Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 7. Global Hepatitis Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 8. Global Hepatitis Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 9. Global Hepatitis Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 10. Global Hepatitis Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 11. Global Hepatitis Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 12. Global Hepatitis Therapeutics Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 13. Global Hepatitis Therapeutics Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 14. U.S. Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 15. U.S. Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 16. U.S. Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 17. Canada Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 18. Canada Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 19. Canada Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 20. UK Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 21. UK Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 22. UK Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 23. Germany Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 24. Germany Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 25. Germany Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 26. RoE Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 27. RoE Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 28. RoE Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 29. China Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 30. China Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 31. China Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 32. India Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 33. India Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 34. India Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 35. Japan Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 36. Japan Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 37. Japan Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 38. RoAPAC Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 39. RoAPAC Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 40. RoAPAC Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 41. Brazil Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 42. Brazil Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 43. Brazil Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 44. Mexico Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 45. Mexico Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 46. Mexico Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 47. RoLA Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 48. RoLA Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 49. RoLA Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 50. Row Hepatitis Therapeutics Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 51. Row Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 52. Row Hepatitis Therapeutics Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 53. List of secondary sources, used in the study of global Hepatitis Therapeutics Market
  • TABLE 54. List of primary sources, used in the study of global Hepatitis Therapeutics Market
  • TABLE 55. Years considered for the study
  • TABLE 56. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Hepatitis Therapeutics Market, research methodology
  • FIG 2. Global Hepatitis Therapeutics Market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Hepatitis Therapeutics Market, key trends 2020
  • FIG 5. Global Hepatitis Therapeutics Market, growth prospects 2021-2027
  • FIG 6. Global Hepatitis Therapeutics Market, porters 5 force model
  • FIG 7. Global Hepatitis Therapeutics Market, pest analysis
  • FIG 8. Global Hepatitis Therapeutics Market, value chain analysis
  • FIG 9. Global Hepatitis Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 10. Global Hepatitis Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 11. Global Hepatitis Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 12. Global Hepatitis Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 13. Global Hepatitis Therapeutics Market by segment, 2018 & 2027 (USD Billion)
  • FIG 14. Global Hepatitis Therapeutics Market, regional snapshot 2018 & 2027
  • FIG 15. North America Hepatitis Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 16. Europe Hepatitis Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 17. Asia pacific Hepatitis Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 18. Latin America Hepatitis Therapeutics Market 2018 & 2027 (USD Billion)
  • FIG 19. Global Hepatitis Therapeutics Market, company market share analysis (2020)